Clinical Trial: Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Advanced HCC
Study Type: OBSERVATIONAL
Official Title: Efficacy Analysis of the Combined Target - Immunotherapy and XELOX Chemotherapy Regimen in the Treatment of Advanced Hepatocellular Carcinoma.
Brief Summary:
In China, primary hepatocellular carcinoma (HCC) has high morbidity and mortality, imposing a heavy burden on the public.Surgical resection is an effective treatment, but as HCC is often latent, less than 30% of patients are suitable for surgery at first diagnosis.So systemic anti-tumor therapy is crucial for advanced HCC.Small-molecule targeted drugs like lenvatinib and sorafenib are NCCN-recommended first-line drugs for advanced HCC.The combination of targeted drugs and immune checkpoint inhibitors can prolong…
Read more